|
Applications
|
In U266 myeloma cells, Nifuroxazide significantly inhibited STAT3 tyrosine phosphorylation in a dose-dependent manner, with an IC50 value of 10 μM. The inhibitory effect of Nifuroxazide on STAT3 tyrosine phosphorylation was rapid, occurring as early as 1 hr after treatment and sustained for at least 24 hrs. In addition, Nifuroxazide did not affect STAT3 serine (727) phosphorylation.
|
|
Applications
|
In 4T1 tumor-bearing mice, Nifuroxazide significantly reduced tumor outgrowth and tumor weight, without causing any significant change in body weight. The immunohistochemical staining results of 4T1 tumors collected on day 31 showed that Nifuroxazide substantially reduced Ki-67-positive cells and increased CC-3-positive cells, indicating that Nifuroxazide inhibited cell proliferation and induced apoptosis in breast tumor tissues by inhibiting Ki-67 and activating caspase-3.
|
|
References:
[1]. Nelson EA, Walker SR, Kepich A, Gashin LB, Hideshima T, Ikeda H, Chauhan D, Anderson KC, Frank DA. Nifuroxazide inhibits survival of multiple myeloma cells by directly inhibiting STAT3. Blood. 2008 Dec 15;112(13):5095-102.
[2]. Yang F, Hu M, Lei Q, Xia Y, Zhu Y, Song X, Li Y, Jie H, Liu C, Xiong Y, Zuo Z, Zeng A, Li Y, Yu L, Shen G, Wang D, Xie Y, Ye T, Wei Y. Nifuroxazide induces apoptosis and impairs pulmonary metastasis in breast cancer model. Cell Death Dis. 2015 Mar 26;6:e1701.
|
